home / stock / meobf / meobf news

MEOBF News and Press, Mesoblast Ltd Ord From 12/29/25

Stock Information
Company Name: Mesoblast Ltd Ord
Stock Symbol: MEOBF
Market: OTC
Website: mesoblast.com
Menu
MEOBF MEOBF Quote MEOBF Short MEOBF News MEOBF Articles MEOBF Message Board
Get MEOBF Alerts

News, Short Squeeze, Breakout and More Instantly...
MEOBF - Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medi...
MEOBF - Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for t...

MEOBF - Mesoblast Participation at Piper Sandler Conference

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37 th Annual Healthcare Conference in New York on December 2–4, 2025. ...

MEOBF - Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive’s Annual Gener...
MEOBF - Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD)...

MEOBF - Mesoblast appoints James M. O'Brien as US-based CFO

2025-11-17 02:32:41 ET Mesoblast ( MESO ) has named James M. O’Brien as its US-based Chief Financial Officer, effective immediately.... Read the full article on Seeking Alpha For further details see: Mesoblast appoints James M. O’Brien as US...

MEOBF - James M. O'Brien Appointed Chief Financial Officer at Mesoblast

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed Ja...
MEOBF - Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration (FDA) has scheduled a meeting in early December to discuss Mesoblast's data ...

MEOBF - Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2025. Mesoblast Chief Executive Dr. Silv...

MEOBF - Mesoblast: Back Pain And Heart Failure Remain Option Value, Not Base Case

2025-10-07 14:57:04 ET Introduction Mesoblast’s stock ( MESO ) is up 70% since my rating upgrade from Sell to Hold in July 2025.... Read the full article on Seeking Alpha For further details see: Mesoblast: Back Pain And Heart Failure Remain Option Val...
Previous 10 Next 10